

DEPARTMENT OF HEALTH & HUMAN SERVICES
Centers for Medicare & Medicaid Services
7500 Security Boulevard
Baltimore, Maryland 21244-1850



CENTER FOR MEDICARE

DATE: August 26, 2022

TO: All Prescription Drug Plans, Medicare Advantage-Prescription Drug Plans, Section 1876 Cost Plans, Medicare-Medicaid Plans, and PACE plans

FROM: Amy Larrick Chavez-Valdez
Director, Medicare Drug Benefit and C & D Data Group

SUBJECT: CY 2023 September Formulary Enhancement Submission Window

CMS is offering a final CY 2023 formulary enhancement submission window prior to the start of the contract year. While Part D sponsors may enhance their formularies at any time, including prior to the start of the contract year, we are offering this additional window to allow another opportunity for plans to submit formulary enhancements so that the Medicare Plan Finder (MPF) displays accurate and up-to-date formulary information during the Annual Election Period (AEP).

Enhancements include the addition of a Part D drug, the movement of a formulary drug to a lower cost-sharing tier, and the removal of utilization management (UM) requirements. Please note that we do not expect sponsors to make significant formulary enhancements during this window, as the formulary that was initially submitted to CMS for review was used to develop the Part D bid. Generic substitutions made in accordance with 42 C.F.R. § 423.120(b)(5)(iv) should be submitted during this window.

The submission window will be open between **12:00 a.m. EDT September 21, 2022 and 5:00 p.m. EDT on September 23, 2022**. An updated CY 2023 formulary reference file (FRF) will be available within the CY 2023 HPMS Formulary Submission Module by close of business on September 15, 2022.

If you have any questions regarding this formulary enhancement window, please email PartDFormularies@cms.hhs.gov.